Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
Part of paid clinical trials in Peoria, Arizona.
- Sponsor
- Biohaven Therapeutics Ltd.
- Study ID
- NCT06309966
- Phase
- PHASE2/PHASE3
- Status
- Active Not Recruiting
Conditions
- Focal Epilepsy
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
Study Details
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
Key Dates
- First listed
- Mar 13, 2024
- Start date
- May 13, 2024
- Status verified
- Jun 2026
- Primary completion
- Oct 31, 2026
- Completion
- Oct 31, 2026
Study Design
- Enrollment
- 390 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: BHV-7000 50 mg
- Experimental: BHV-7000 75 mg
- Placebo Comparator: Placebo
Primary Outcome Measure
Change from Baseline in 28-day average seizure frequency [ Time Frame: Baseline, Week 8 to Week 16 ]
Locations (50)
Find similar trials in Peoria, AZ
Related Studies
- Diffusion MRI Methods to Minimize Postoperative Deficits in Pediatric Epilepsy SurgeryRecruiting · Wayne State University · Detroit, Michigan
- An Open-label Study of XEN1101 in EpilepsyPHASE3 · Enrolling By Invitation · Xenon Pharmaceuticals Inc. · Phoenix, Arizona
- Sleep Architecture & Cognition in Focal EpilepsyRecruiting · University of California, Davis · Sacramento, California
- Breathing Rescue for SUDEP PreventionRecruiting · The University of Texas Health Science Center, Houston · Houston, Texas